Testing a new cancer treatment alone and with immunotherapy drugs

Plain-English translation of NCT05581004 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage trial testing a new medication called in patients with advanced solid cancers. Researchers want to understand how safe the medication is, how your body processes it, and whether it can help shrink tumors. The study also tests whether combining this medication with existing immunotherapy drugs (like or ) works better than the new treatment alone.

Currently, many patients with advanced cancers have limited treatment options. This medication is being studied to see if it offers a new way to fight cancer, potentially working even better when combined with immunotherapy drugs that help your immune system attack cancer cells.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced or metastatic solid cancer (including lung, head and neck, melanoma, breast, esophageal, gastric, cervical, colorectal, bladder, kidney, or liver cancer)
your cancer cannot be cured with surgery alone
you are well enough to handle treatment (generally able to care for yourself with minimal assistance)
you have a life expectancy of at least 12 weeks
you have measurable disease that can be tracked on scans
your tumor tissue is available for the research team to study

You likely don't qualify if…

you are pregnant, breastfeeding, or planning to become pregnant within 4 months after treatment ends
you have received other cancer treatments (chemotherapy, radiation, or experimental drugs) within 3 weeks before starting this study
you have active or untreated cancer that has spread to your brain
you have a history of autoimmune disease or active hepatitis B, hepatitis C, tuberculosis, or HIV
you have received a live vaccine within 4 weeks before starting treatment

What participation looks like

You would receive intravenous infusions of the medication on the first day of each 21-day cycle. Depending on which group you're assigned to, you might receive the new medication alone, or combined with one of the existing immunotherapy drugs. You would continue treatment until your cancer stops responding, side effects become too severe, or you choose to stop. Throughout the trial, you'll have regular blood tests, scans, and medical check-ins to monitor how the treatment is working and how you're tolerating it.

AI-generated summary from trial data · Jul 8, 2026 · Not medical advice

Testing a new cancer treatment alone and with immunotherapy drugs

What is this trial?

Do you qualify?

What participation looks like

Trial locations